The Lancet Oncology

Aims & Scope

The Lancet Oncology publishes interesting and informative reviews on any topic connected with oncology, and considers any original research contribution that advocates change in, or illuminates, oncological clinical practice.

Topics include, but are not limited to: Breast cancer; Endocrine system cancer; Gastrointestinal cancer; Genitourinary cancer; Gynaecological cancer; Haematological cancer; Head and neck cancer; Neurooncology; Paediatric oncology; Thoracic oncology; Sarcoma; Skin cancer; Epidemiology, cancer prevention, and cancer control; Supportive care; Imaging; Health-care systems.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	35.9
2024	41.60

SJR (SCImago Journal Rank)

Year	Value
2024	11.319

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	432

Journal Rank

Year	Value
2024	68

Journal Citation Indicator

Year	Value
2024	15163

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

  Citation: 6338

  Authors: Roger, Monika E, Warren P, Martin J, Martin JB, Robert C, Samuel K, Anouk, Barbara, Karl, Peter, Alba A, Johanna, Christine, Charles J, Karima, Pieter, Salvador, Elizabeth, Thierry, Michael, Denis, J Gregory, René-Olivier

• Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

  Citation: 4764

  Authors: Ann-Lii, Yoon-Koo, Zhendong, Chao-Jung, Shukui, Jun Suk, Rongcheng, Jifeng, Shenglong, Tsai-Sheng, Jianming, Yan, Houjie, Jiwei, Jiejun, Won Young, Hongming, Karin, Jessie, Dimitris, Zhongzhen

• Definition and classification of cancer cachexia: an international consensus

  Citation: 4490

  Authors: Kenneth, Florian, Stefan D, Ingvar, Eduardo, Robin L, Aminah, Charles, Neil, Giovanni, Mellar, Maurizio, Faith, Lukas, Paula, Declan, Andrew, Stein, Vickie E

• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

  Citation: 4315

  Authors: Rafael, Enric, Radj, Alain, Bartomeu, Enriqueta, Ramon, Ramon, Cinta, Jose Miguel, Rut, Manuel, Pilar, Flavia, Teresa, Amelia, Filippo, Romain, Isabel, Alfonso, Eric, Javier, Michele, Noemi, Giuseppe, Ulpiano, Mariano, Miguel Angel, Josefa, Jose, Javier, Dolores, Manuel, Olivier, Julien, Nathalie, Rosario, Gilles, Delvys, Guillermo, Vittorio, Lioba, Pierre, Reyes, Alessandra, Angel, Enrico, Christian, Maria, Ana, Cristina, Itziar, Jose Luis, Jose Javier, Miguel Angel, Miquel, Luis

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  Citation: 3773

  Authors: S Vincent, Meletios A, Antonio, Joan, Giampaolo, María-Victoria, Shaji, Jens, Efstathios, Paul, Ola, Bruno, Angela, Brendan, Xavier, Sonja, Sagar, Laura, Elena, Sundar, Orhan, Sigurdur Y, Jo, Saad Z, Juan José, Hans Erik, Meral, Michele, Hartmut, Evangelos, Robert A, Kenneth C, Brian G M, Jesus F San

• Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

  Citation: 3372

  Authors: Wenhua, Weijie, Ruchong, Wei, Jianfu, Ke, Caichen, Qing, Weixiang, Hengrui, Shiyue, Jianxing

• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

  Citation: 3232

  Authors: Tetsuya, Satoshi, Yasushi, Shunichi, Isamu, Junji, Takashi, Miyako, Hirohito, Tomonori, Kazuhiro, Nobuyuki, Minoru, Hiroshige, Kazuhiko, Shinzoh, Eiji, Hiroshi, Shinichi, Kazuhiko, Masahiro

• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

  Citation: 3153

  Authors: Caicun, Yi-Long, Gongyan, Jifeng, Xiao-Qing, Changli, Shucai, Jie, Songwen, Shengxiang, Shun, Li, Chengping, Chunhong, Yi, Lei, Ming, Jianan, Xiuyi, Yiping, Qingyu, Jun, Li, Changxuan

• Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

  Citation: 2778

  Authors: Walter, Uwe, Thomas, Otmar Dieter, Friedhelm, Hans-Jürgen

• Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

  Citation: 2596

  Authors: Carla MM, Jessica R, Linda J, Tony, Michael B, Lisa, Vickie E

---